ストックスクリーナーアプリを入手
2.57
0.39%
0.010
アフターアワーズ：
2.52
-0.05
-1.95%
前日終値:
$2.56
開ける：
$2.6
24時間の取引高:
36,260
Relative Volume:
0.81
時価総額：
$57.60M
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-11.38%
1か月 パフォーマンス:
-26.15%
6か月 パフォーマンス:
+0.00%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$2.55
$2.67
1週間の範囲:
$2.4476
$3.0782
52週間の値動き範囲:
$2.4476
$12.50
Kalaris Therapeutics Inc Stock (KLRS) Company Profile
名前
Kalaris Therapeutics Inc
セクター
電話
650-249-2727
住所
628 MIDDLEFIELD ROAD, PALO ALTO
KLRS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
KLRS
Kalaris Therapeutics Inc
|
2.57 | 57.60M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
448.40 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
513.58 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
312.32 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
537.92 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
252.78 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Kalaris Therapeutics Inc Stock (KLRS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-05-07 | 開始されました | Leerink Partners | Outperform |
| 2025-04-08 | 開始されました | William Blair | Outperform |
Kalaris Therapeutics Inc (KLRS) 最新ニュース
Kalaris Therapeutics, Inc.Common Stock (Nasdaq:KLRS) Stock Quote - FinancialContent
Kalaris to Present at Noble Capital Markets 2025 Emerging Growth Equity Conference - The Manila Times
Kalaris Therapeutics CEO Reveals Latest Retinal Disease Progress at Noble Capital Conference - Stock Titan
Kalaris: Phase 1 Trial for TH103 Advances Following AlloVir Merger and Other Important Updates - TradingView
Kalaris to Participate at Stifel Ophthalmology Forum - The Manila Times
Kalaris Leadership Team to Reveal Latest Ophthalmology Strategy at Prestigious Stifel Forum - Stock Titan
Pre-market Movers: IXHL, KLRS, HCTI, DOCS... - RTTNews
Kalaris Therapeutics Reports Q1 2025 Financials and Progress - TipRanks
Kalaris Therapeutics, Inc. SEC 10-Q Report - TradingView
Kalaris Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Kalaris Therapeutics reports Q1 EPS ($2.52) vs ($2.60) last year - TipRanks
Kalaris Reports First Quarter 2025 Financial Results and Provides Business Highlights - The Manila Times
Kalaris Eyes Breakthrough in AMD Treatment: Phase 1 Trial Progress and $101M War Chest Revealed in Q1 Earnings - Stock Titan
Kalaris Therapeutics restructures executive compensation By Investing.com - Investing.com South Africa
Kalaris Therapeutics restructures executive compensation - Investing.com
Kalaris Therapeutics Amends Executive Employment Agreements - TipRanks
Kalaris Therapeutics initiated with an Outperform at William Blair - MSN
AlloVir Announces FDA Clearance of Investigational New Drug Application for ALVR106, an Allogeneic, Off-The-Shelf, Multi-Virus Specific T Cell Therapy Targeting Four Devastating Respiratory Viruses - MarketScreener
William Blair initiates Kalaris stock with Outperform rating By Investing.com - Investing.com UK
William Blair Initiates Kalaris Therapeutics With Outperform Rating - marketscreener.com
Kalaris Therapeutics appoints new board chair By Investing.com - Investing.com Canada
The Gross Law Firm Notifies Shareholders of AlloVir, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of March 19, 2024(NASDAQ: ALVR) - MarketScreener
Kalaris Therapeutics appoints new board member - Investing.com Australia
Kalaris Therapeutics Appoints Leone Patterson to Board - TipRanks
Kalaris Therapeutics appoints new board member By Investing.com - Investing.com Canada
Kalaris Therapeutics appoints new board chair - Investing.com Australia
Kalaris Expands Board Of Directors Appointing Leone Patterson As Chair Of Audit Committee - marketscreener.com
Kalaris Expands Board of Directors Appointing Leone Patterson as Chair of Audit Committee - TradingView
Aviceda Therapeutics Appoints Industry Veteran Dr. Jeffrey Nau as Chief Executive Officer to Lead Next Phase of Growth and Innovation - 01net
ALLOVIR INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In AlloVir To Contact Him Directly To Discuss Their Options - MarketScreener
ALVR Bronstein, Gewirtz & Grossman LLC Announces that AlloVir Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - MarketScreener
KLRS stock touches 52-week low at $7.75 amid market challenges - Investing.com
The Law Offices of Vincent Wong Remind AlloVir Investors of a Lead Plaintiff Deadline of March 19, 2024 - MarketScreener
ROSEN, SKILLED INVESTOR COUNSEL, Encourages AlloVir, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionALVR - MarketScreener
Class Action Filed Against AlloVir, Inc. (ALVR) Seeking Recovery for InvestorsContact Levi & Korsinsky - MarketScreener
ALLOVIR SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In AlloVir To Contact Him Directly To Discuss Their Options - Marketscreener.com
Levi & Korsinsky Notifies AlloVir, Inc.(ALVR) Investors of a Class Action Lawsuit and Upcoming Deadline - MarketScreener
Kalaris Therapeutics’ chief accounting officer sells shares worth $8,135 - Investing.com India
Kalaris Therapeutics’ chief accounting officer sells shares worth $8,135 By Investing.com - Investing.com UK
Kalaris and AlloVir Inc. complete merger - Ophthalmology Times
Kalaris Therapeutics Announces Closing of Merger With AlloVir - VisionMonday.com
Kalaris Therapeutics Inc. (KLRS) - Zacks Investment Research
ALLOVIR, INC. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a class action lawsuit has been filed in the United States District Court for the District of Massachusetts against AlloVir, Inc. - Marketscreener.com
KLRS Stock Price and Chart — NASDAQ:KLRS - TradingView
Kalaris Therapeutics Completes Merger with AlloVir -March 19, 2025 at 04:18 am EDT - Marketscreener.com
AlloVir Merges with Kalaris Therapeutics, Inc. - TipRanks
Kalaris Therapeutics Completes Merger with AlloVir, Advances Phase 1 Trial of TH103 for Neovascular Retina Diseases - Nasdaq
Kalaris Secures $100M War Chest for Revolutionary Macular Degeneration Treatment - StockTitan
Shootin' the Bull about cattle feeders - The Globe and Mail
Kalaris Therapeutics Inc (KLRS) 財務データ
Kalaris Therapeutics Inc (KLRS) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
2.13%
1.01%
大文字化:
|
ボリューム (24 時間):